Sandra Breene is taking on one of the world’s most iconic races after overcoming a life-changing cancer diagnosis.

As treatment options expand in chronic lymphocytic leukemia (CLL), the benefits and limitations of fixed-duration regimens in ...

Most patients initiated full-dose ibrutinib, while reduced starting doses clustered in older, more comorbid, poorer ECOG ...

Pharmac estimates the new approach will save approximately 3,700 infusion hours annually, easing pressure on oncology ...

New research is helping to change the way investigators and clinicians think about and treat Richter transformation (RT) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic ...

Patients with chronic lymphocytic leukemia show higher risks for skin cancer, as well as skin cancer-specific metastasis and ...

Despite major advances in targeted therapy, chronic lymphocytic leukemia (CLL) remains largely incurable. Resistance to ...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic ...

James E. Dentzer said, "we sold what was remaining to Oberland to clean it all up. We are now completely independent of the Erivedge stream," emphasizing an operational pivot from legacy assets.

CLL is linked to higher skin cancer risk and worse outcomes. Learn more about this large cohort study and its clinical ...

Associate Health Minister David Seymour welcomes Pharmac's decision to fund two new combination therapies for people with chronic lymphocytic ...